Loading
CRISPR and Genetic Engineering / Cancer Research and Treatments · Journal article
Frontiers in Microbiology · August 5, 2026
Raises a question worth testing. It does not answer one.
This narrative review surveys bacteriophage applications in livestock, poultry, and aquaculture, emphasizing mechanistic potential and translational bottlenecks rather than reporting clinical evidence. The authors acknowledge that most evidence remains preclinical and highlight inconsistent experimental outcomes, regulatory fragmentation, and substantial gaps between laboratory findings and veterinary practice.
Narrative review. Livestock, poultry, and aquaculture systems in the context of antimicrobial resistance prevention and control.
Bacteriophages can be engineered as multifunctional platforms integrating direct killing, immune modulation, and antigen delivery Most evidence remains preclinical with substantial translational gaps Inconsistent experimental outcomes reported for claimed advantages such as microbiota preservation and biofilm penetration
No efficacy, safety, or pharmacokinetic data reported for any specific intervention Host range constraints, pharmacokinetic limitations, and regulatory fragmentation identified as major bottlenecks
This review identifies bacteriophages as a research direction under investigation for antimicrobial resistance mitigation in animal production, but emphasizes that preclinical status and inconsistent outcomes mean adoption in veterinary practice is not yet supported by adequate evidence. Clinicians should view phage therapy in animals as experimental pending translational advances and regulatory harmonization.
A narrative review synthesizing preclinical mechanistic advances and identifying translational gaps rather than reporting clinical trial data or definitive evidence of efficacy in animals.
As stated by the source record.
This review identifies bacteriophages as a research direction under investigation for antimicrobial resistance mitigation in animal production, but emphasizes that preclinical status and inconsistent outcomes mean adoption in veterinary practice is not yet supported by adequate evidence. Clinicians should view phage therapy in animals as experimental pending translational advances and regulatory harmonization.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The global spread of antimicrobial resistance (AMR) has intensified the search for alternatives to conventional antibiotics in animal production systems. Bacteriophages can be engineered beyond narrow-spectrum antibacterial agents into multifunctional biological platforms that integrate direct killing, immune modulation, and antigen delivery. We summarize recent advances across livestock, poultry, and aquaculture, delineating mechanistic distinctions between lytic phage therapy, phage display-derived interventions, and engineered platforms including CRISPR-Cas-enabled theranostic systems. However, as detailed below, most evidence remains preclinical, and translational gaps are substantial. Unlike prior descriptive reviews, we analyze translational bottlenecks—host range constraints, pharmacokinetic limitations, regulatory fragmentation—and assess the existing research evidence for claimed advantages such as microbiota preservation and biofilm penetration while upfront acknowledging inconsistent experimental outcomes and inherent application limitations behind these beneficial effects. We conclude that realizing phages’ therapeutic potential in veterinary medicine requires coordinated progress in synthetic biology, scalable manufacturing, and regulatory harmonization within a One Health framework.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.